Guineesine (or guineensine) is a compound isolated from long pepper (Piper longum)[1] and black pepper (Piper nigrum).[2]
Clinical data | |
---|---|
Other names | Guineensine; UNII-7DK8DMU9JX |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
ChEBI |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C24H33NO3 |
Molar mass | 383.532 g·mol−1 |
3D model (JSmol) |
|
| |
|
It was first isolated, studied and named from Piper guineense.[3][4]
Guineensine inhibits the cellular reuptake of anandamide and 2-arachidonoylglycerol in a mouse model (EC50 = 290 nM).[5] [6] This causes an increase in the activity of the two neurotransmitters which are classified as endogenous cannabinoids.
Guineesine can dose-dependently produce cannabimimetic effects in a mouse model[5] which are indicated by potent catatonic, analgesic, hypo-locomotive and hypo-thermic effects. In addition, the analgesic and catatonic effects were reversed by the cannabinoid receptor type 1 (CB1) inverse agonist rimonabant.[5]
Guineesine is also a monoamine oxidase inhibitor (MAOI) in vitro (IC50 = 139.2 μM).[7]